Trovagene, Inc. Information

Trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics.  Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.  Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. Trovagene's lead therapeutic asset is PCM-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (PLK1) inhibitor for the treatment of acute myeloid leukemia (AML). Among the four members of the PLK family, PLK1 is recognized to be the fundamental component for cell division to take place correctly. Most importantly, PLK1 is only expressed in dividing cells, whereas other PLK members are expressed in differentiated post-mitotic cells, like neurons, indicating a potentially better safety profile for a PLK1-selective inhibitor, such as PCM-075. The greatest clinical activity for PLK inhibitors has been observed in AML, which may likely be due to the highly proliferative nature of AML tumors. Trovagene's interest in PLK inhibitors stems from this observed PLK clinical activity and the opportunity for a more selective therapeutic approach. The properties of PCM-075 are PLK1 selectivity, the only orally-available PLK inhibitor in clinical development, a short half-life of ~24 hours with reversible hematologic toxicities, and an acceptable safety profile in humans with no adverse respiratory or cardiovascular effects. Trovagene plans to conduct a phase 1/2 trial for determining dose, patient response and correlative biomarker analysis for patients with AML. For more information, please visit our website www.trovagene.com.